Beckman Coulter Life Sciences (Indianapolis, IN) has agreed to acquire flow cytometer developer Xitogen Technologies (Suzhou, China). The acquisition includes fully staffed facilities in Suzhou and Dalian, China, which will function as research and development and manufacturing centers for the company. Financial details were not disclosed.
Related: Future cytometry: Going with—or without—the flow
In addition to providing an operational base in the China market, Xitogen will provide Beckman Coulter with a research instrument to round out their cytometry offering. Xitogen developed the XTG-1600, a small-footprint cytometer that can detect viruses, bacteria, microparticles, and cell organelles in the 100 nm range for basic research investigations. The base single-laser, four-channel system can be incrementally expanded to a three-laser, 16-channel configuration.
"Having an operational base in the growing Asian market will enable us to provide timely service to customers in that region," says Mario Koksch, vice president and general manager of the Cytometry Business Unit for Beckman Coulter Life Sciences. "Adding this technology and intellectual property to our existing portfolio means we can extend our reach from clinical diagnostics through clinical research and further into basic research."
The acquisition is expected to close in the second quarter of 2014.
Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!